Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 9/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | HPGD | P15428 | 7/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3543307 | 0.90 | KDM4E (0.65) | ANO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2294234 | 0.88 | L3MBTL1 (0.55) | ANO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2843961 | 0.87 | ANO1 (0.51) | ANO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3539261 | 0.85 | KDM4E (0.68) | ANO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL13980516 | 0.81 | KDM4E (0.69) | KDM4EALDH1A1HPGDHSD17B10RXFP1 | |
| SCHEMBL120304 | 0.81 | RAB9A (0.56) | ANO1KDM4EALDH1A1HSD17B10MEN1 | |
| SCHEMBL3545360 | 0.79 | ANO1 (0.63) | ANO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10240860 | 0.78 | ANO1 (0.42) | ANO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10240087 | 0.78 | PDK1 (0.39) | ANO1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3541346 | 0.78 | KDM4E (0.65) | ANO1KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722688-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-13 | — | — | US | disclosed |
| US-8309558-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-8148382-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316126-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ANO1 1786/4885KDM4E 4218/4885ALDH1A1 239/4885 |
| US-20130197012-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ANO1 1786/4885KDM4E 4218/4885ALDH1A1 239/4885 |
| US-20120201783-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, SLC10A1 | ANO1 1786/4885KDM4E 4218/4885ALDH1A1 239/4885 |
| US-20110256099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ANO1 1786/4885KDM4E 4218/4885ALDH1A1 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.